RGEN News and Press, Repligen Corporation From 10/28/21

Repligen shares rise (RGEN +6.2%) after the company posted third-quarter profit and revenue that beat Wall Street estimates and raised its FY forecast. The company raised its profit per share forecast for the year to a range of $2.86-$2.91, up from a prior guidance of $2.71-$2.78. Total reven...

Repligen (NASDAQ:RGEN): Q3 Non-GAAP EPS of $0.78 beats by $0.30; GAAP EPS of $0.58 beats by $0.10. Revenue of $178.22M (+89.5% Y/Y) beats by $14.25M. Shares +0.52% PM. Press Release Inorganic revenue from acquisitions made in 2020 and 2021 accounted for 6% of revenue. Adjusted gross margin in...

Reports record revenue of $178.2 million for the quarter, representing year-over-year growth of 89% and organic growth of 77% Raises revenue guidance to $655-$665 million for full year 2021 Completes acquisition of affinity ligands innovator Avitide Inc. WALTHA...

Webcast and Conference Call to Be Held Thursday, October 28, 2021 at 8:30 a.m. EDT WALTHAM, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2021 financial results on Thursday, October 28, 2021...

One of the biggest hurdles people face when they think about buying stocks is feeling like they don't have enough money to make a difference. But over time, even a little bit of money can grow into an impressive portfolio. In the last 40 years, the S&P 500 index has gained 3,600%. ...

Proposed acquisition strengthens Repligen’s Proteins business Adds a market leader in affinity ligand discovery and development and complements established partnership with Navigo GmbH Strategically moves Repligen into affinity resin solutions for gene therapy ...

After the recent era of value expansion due to the pandemic and fiscal policy, the use of unbiased rankings may allow for long-term success. As valuations come back down to historical levels, as very few would claim they will stay elevated perpetually, holding the right stocks will be...

WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), today announced they have completed development and validation of a novel protein...

The Fed’s creation of money is here to stay. U.S. inflation and debt monetization have fully engaged. 40 stocks I’d rather be in than government debt. One simple solution for trend identification that’s worked for more than 20 years in indices, currencies ...

Horizon Therapeutics has now reached a growth point that is supportive of long-term success due to multiple eggs in the basket. The company has 11 FDA approved drugs and 10 phase 2 or 3 clinical trials underway, with revenue growth currently averaging 91% per year over the past 10 yea...